Autologous Antigen-presenting Cells Efficiently Expand Transposon CAR-T Cells with Predominant Memory Phenotype
Overview
Authors
Affiliations
The quality of chimeric antigen receptor (CAR)-T cell products, including the expression of memory and exhaustion markers, has been shown to influence their long-term functionality. The manufacturing process of CAR-T cells should be optimized to prevent early T cell exhaustion during expansion. Activation of T cells by monoclonal antibodies is a critical step for T cell expansion, which may sometimes induce excess stimulation and exhaustion of T cells. Given that transposon (PB)-based gene transfer could circumvent the conventional pre-activation of T cells, we established a manufacturing method of PB-mediated HER2-specific CAR-T cells (PB-HER2-CAR-T cells) that maintains their memory phenotype without early T cell exhaustion. Through stimulation of CAR-transduced T cells with autologous peripheral blood mononuclear cell-derived feeder cells expressing both truncated HER2, CD80, and 4-1BBL proteins, we could effectively propagate memory-rich, PD-1-negative PB-HER2-CAR-T cells. PB-HER2-CAR-T cells demonstrated sustained antitumor efficacy and debulked the HER2-positive tumors . Mice treated with PB-HER2-CAR-T cells rejected the second tumor establishment owing to the expansion of PB-HER2-CAR-T cells. Our simple and effective manufacturing process using PB system and genetically modified donor-derived feeder cells is a promising strategy for the use of PB-CAR-T cell therapy.
Capolla S, Rasool M, Toffoli G, Dal Bo M Cancer Med. 2025; 14(5):e70726.
PMID: 40013750 PMC: 11866474. DOI: 10.1002/cam4.70726.
Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells.
Mitsuno K, Suematsu M, Naito Y, Mayumi A, Yoshida H, Osone S Cancer Immunol Immunother. 2025; 74(3):79.
PMID: 39891728 PMC: 11787079. DOI: 10.1007/s00262-024-03927-8.
Lighting the way: an economical alternative to feeder cell irradiation for T-cell expansion.
Benavidez Arias M, Nguyen A, Ross D, Eagerton D, Ritthipichai K Front Immunol. 2024; 15:1453740.
PMID: 39346913 PMC: 11427811. DOI: 10.3389/fimmu.2024.1453740.
Mucha M, Stach M, Kastankova I, Rychla J, Vydra J, Lesny P Front Immunol. 2024; 15:1415328.
PMID: 39192973 PMC: 11347927. DOI: 10.3389/fimmu.2024.1415328.
Skeate J, Pomeroy E, Slipek N, Jones B, Wick B, Chang J Mol Ther. 2024; 32(6):1817-1834.
PMID: 38627969 PMC: 11184336. DOI: 10.1016/j.ymthe.2024.04.024.